Produktname:benzyl piperazine-1-carboxylate

IUPAC Name:benzyl piperazine-1-carboxylate

CAS:31166-44-6
Molekulare Formel:C12H16N2O2
Reinheit:95%+
Katalognummer:CM103953
Molekulargewicht:220.27

Packungseinheit Verfügbarer Vorrat Preis($) Menge
CM103953-100g in stock țư
CM103953-500g in stock ưțƀ

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

   refresh    

Produkt-Details

CAS-Nr.:31166-44-6
Molekulare Formel:C12H16N2O2
Schmelzpunkt:-
SMILES-Code:O=C(OCC1=CC=CC=C1)N1CCNCC1
Dichte:
Katalognummer:CM103953
Molekulargewicht:220.27
Siedepunkt:
Mdl-Nr.:MFCD00274317
Lagerung:

Category Infos

Piperazines
Piperazine is an organic compound consisting of a six-membered ring containing two nitrogen atoms in opposite positions in the ring. The chemical formula of piperazine is C4H10N2, and it is an important pharmaceutical intermediate. Pyrimidines and piperazines are known to be the backbone of many bulk compounds and important core structures for approved drugs; studies have shown that combining a pyridine ring with a piperazine moiety within a single structural framework enhances biological activity.
Benzenes
Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

Column Infos

RMC-6236
Over 30% of all human cancers, including a certain percentage of pancreatic, colorectal, lung cancers, and AML are driven by mutations of RAS genes. There is a significant unmet medical need in RAS mutant cancers.
Revolution Medicines’ investigational drug, RMC-6236 is an oral, non-covalent, RAS (ON) inhibitor that is selective for the active, GTP-bound state of both mutant and wild-type variants of the canonical RAS isoforms. RMC-6236 is under clinical phase I studies as monotherapy in NSCLC and PDAC, and advanced solid tumors with KRAS G12X mutations harboring KRAS G12X mutations.

Related Products